Clinical Trials of SGLT2 Inhibitors in the Management of Heart Failure

Global prevalence of Heart Failure is 64.34 million cases, accounting for 9.91 million years lost due to disability. Despite the paradigm shift of HF therapy over the last four decades, still, the risk of mortality remains high. In this Expert talk, we will discuss the Pleiotropic effects of SGLT2 inhibitors, and highlight its cardioprotective theories in the prevention of cardiovascular events. Also, to emphasize the key results of global clinical trials and implement strategies to increase the...